Anti-Fungal Treatment Market

Antifungal Treatment Market Research, 2032

Anti-Fungal Treatment Market is expected to grow at a CAGR of 3.3% in the forecast period (2023-2032), with the market size valued at USD 12.27 billion in 2021 and projected to reach USD 17.4 billion by 2032.

Fungi are microorganisms that can survive in a variety of conditions and cause different type of illnesses in people, ranging from skin infections to systemic infections by inhalation. These illnesses are frequently caused by exposure to unsanitary conditions or by impaired immune systems. As a result, people may have fungal infections on their skin, hair, and lungs, fueling market expansion. This proliferation is being aided by common fungal infections such as ringworm, athlete's foot, and fungal nail infections. Antifungal medications are critical in avoiding fungal growth and infection especially over-the-counter choices for skin infections, is favorably boosting the growth of the antifungal drug industry.

Market Highlights 

Anti-Fungal Treatment Market is expected to exhibit a CAGR of 3.3% during the forecast period.

Anti-Fungal Treatment Market is expected to reach USD 17.4 billion, growing at a CAGR of 3.3% owing to the global rise in the occurrence of fungal infections that has driven producers to create enhanced formulation drugs for better clinical outcomes. This, in turn, is fuelling market expansion throughout the predicted period. As a result, producers are focused on new drug formulations that can be manufactured utilizing nanotechnology.

Anti-Fungal Treatment Market Segmentation

Azoles segment to grow rapidly due to their fungicidal qualities

Based on the Drug Type, the market is divided into Echinocandins, Azoles, Polyenes, and Allylamines. In 2022, Azoles sector led the market, and it is predicted to dominate throughout the projection period. The market for azoles, which include systemic antifungal medications like fluconazole and ketoconazole that are highly recommended for treating fungal infections, is expected to expand. Due to their affordability and effectiveness in treating invasive systemic fungal infections, echinocandins, notably micafungin and caspofungin, derived from natural fungal sources, are anticipated to have the highest CAGR during forecasted period.

Topical category to expand due to their increased usage globally

By Route of Administration, the Anti-Fungal Treatment Market is segmented into Oral, Topical, and Parenteral. Topical segment sector led the market, and it is predicted to dominate throughout the projection period.  Due to a rise in the use of topical medications around the world, the topical antifungal mode of administration has the biggest market share for antifungal medications. Additionally, the market is benefiting from the expanding use of topical medications by doctors to treat dermatological fungal infections.

Market Dynamics

Growth Drivers

Increase in Nosocomial Infections to Boost the Market for Antifungal Drugs

Fungal infections have become a major public health concern around the world in recent years. Furthermore, the prevalence of nosocomial infections is fueling market expansion. The increasing occurrences of cancer, an increase in hematopoietic stem cell transplantation, and other factors that result in immune system weakness are to blame for the rise in nosocomial infections. Aspergillosis, for example, is typically found in patients who are immunocompromised to varying degrees.  According to the World Health Organization (WHO), roughly 30% of patients in intensive care units in high-income countries have at least one healthcare-associated infection. In contrast, the frequency of intensive care-acquired infection is 2-3 times higher in middle to low-income nations than in high-income ones. The rising frequency of hospital-acquired infections is predicted to supplement and drive the market's expansion.

Increased R&D efforts are Expected to Boost the Market Growth

Increasing prevalence of fungal diseases and the difficulties in treating them increased investment in research and development (R&D) operations, which result in the creation of new antifungal medications. Currently, commonly used antifungal medicines have limits, particularly in treating invasive infections, necessitating the development of novel formulations. The high morbidity and mortality rates linked with yeast infections highlight the need for better treatments. Resistance to existing aspergillosis treatments, as well as recurring toxicity problems, are driving R&D and clinical trials for innovative antifungal medications. Major pharmaceutical corporations are actively involved in a variety of R&D projects in this field.

Restraints

High Adverse Effects and the Use of Conventional Drugs is Hurting the Market

Growing availability of expensive and generic medications for the routine treatment of a fungal infection is limiting market expansion. Additionally, the market's expansion is being hampered by the substantial side effects of the antifungal medications used to treat fungal infections. Amphotericin B, for instance, which is widely recommended for fungal infections, has several negative side effects. Furthermore, during the projected period, the market would be hampered by strict government regulations, patent expirations, an increase in fungal resistance, and fake medications.

Recent Developments

• Pfizer announced in March 2022 that the European Medicines Evaluation Agency had authorized their novel antifungal medicine Vfend (voriconazole) for the treatment of potentially deadly fungal infections.
• Basilea Pharmaceutica Ltd. announced in January 2018 the completion of the licensing deal extension with Pfizer for the antifungal Cresemba for China and the Asia Pacific.

Key Players:

• Pfizer Inc.
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Astellas Pharma Inc.
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Sanofi S.A.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Basilea Pharmaceutica AG
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Anti-Fungal Treatment Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America is predicted to lead the global market, owing to increased hygiene awareness, an increase in the frequency of fungal diseases, and the use of sophisticated therapies. Because of improved healthcare infrastructure, greater healthcare spending, and an increasing number of patients with fungal infections, Europe is expected to hold the second-largest market share.

Anti-Fungal Treatment Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Anti-Fungal Treatment Market Scope and Segments:

Frequently Asked Questions (FAQ):